血清肌抑素水平与胃癌恶病质的关系

被引：2

作者：

曹淑成

丁连安

牛冬光

王琳

姚如永

机构：

[1] 青岛大学医学院附属医院东区普外科

[2] 青岛大学医学院附属医院中心实验室

来源：

中华临床营养杂志 | 2012年 / 05期

关键词：

肌抑素; 恶病质; 整体营养状况主观评估; 肿瘤坏死因子-α; 胃癌;

D O I：

暂无

中图分类号：

R459.3 [饮食疗法、临床营养学];

学科分类号：

100215 ;

摘要：

目的观察胃癌恶病质患者血清肌抑素水平变化,并初步探讨肌抑素与肿瘤坏死因子-α的相关性。方法根据整体营养状况主观评估(PG-SGA)分级将80例胃癌患者分成胃癌恶病质组(PG-SGAC级,32例)和胃癌非恶病质组(PG-SGA A+B级,48例),采用ELISA法测定血清肌抑素和肿瘤坏死因子-α水平,并记录身高、体质量、总蛋白、白蛋白、血红蛋白、C-反应蛋白等指标。对照组为健康体检者80例,同法测定并记录上述指标。结果胃癌恶病质组的血清肌抑素水平为(1.36±0.50)μg/L,显著高于胃癌非恶病质组的(0.91±0.49)μg/L(X~2=14.67,P=0.00);对照组的血清肌抑素水平为(0.70±0.37)μg/L,显著低于胃癌非恶病质组(X~2=36.45,P=0.00)。对照组(r=-0.16,P=0.16)、胃癌非恶病质组(r=0.08,P=0.58)及胃癌恶病质组(r=0.18,P=0.31)中血清肌抑素与肿瘤坏死因子-α浓度均不具有相关性。结论胃癌恶病质患者血清肌抑素水平升高;血清肌抑素与肿瘤坏死因子-α无相关性。

引用

共 33 条

[1]

Functional improvement of dystrophic muscle by myostatin blockade. Bogdanovich S,Krag T O,Barton E R,et al. Nature . 2002

[2]

Myostatin negatively regulates satellite cell activation and self-renewal. McCroskery S,Thomas M,Maxwell L,et al. Journal of Cell Biology,The . 2003

[3]

Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Kambadur R,Sharma M,Smith TP,et al. Genome Research . 1997

[4] ATP-泛素-蛋白酶体途径在癌性恶液质肌萎缩中作用的研究进展 [J].

袁磊 ;

吴国豪 .

中国临床医学, 2008, 15 (06) :914-916

[5]

Targeting the myostatin signaling pathway to treat muscle wasting diseases[J] . H.Q. Han,William E. Mitch. &nbspCurrent Opinion in Supportive & Palliative . 2011 (4)

[6]

Definition and classification of cancer cachexia: an international consensus[J] . Kenneth Fearon,Florian Strasser,Stefan D Anker,Ingvar Bosaeus,Eduardo Bruera,Robin L Fainsinger,Aminah Jatoi,Charles Loprinzi,Neil MacDonald,Giovanni Mantovani,Mellar Davis,Maurizio Muscaritoli,Faith Ottery,Lukas Radbruch,Paula Ravasco,Declan Walsh,Andrew Wilcock,Stein Kaasa,Vickie E Baracos. &nbspLancet Oncology . 2011 (5)

[7]

Nutritional status assessed by the Patient-Generated Subjective Global Assessment (PG-SGA) is associated with qualities of diet and life in Korean cerebral infarction patients[J] . Hyun Jung Lim,Ryowon Choue. &nbspNutrition . 2010 (7)

[8] Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival [J].